Quadram Institute Bioscience is delighted to announce the appointment of three new members to its Board of Trustees.
Dr Celia Caulcott, Dr Bénédicte Flambard, and Professor Peter J. Morgan collectively bring a wealth of experience and knowledge to the QIB leadership.
“On behalf of the Board of Trustees, I’m delighted to welcome Celia, Bénédicte and Peter to join us at this exciting time for the organisation, “ said Dr Tim Brears, Chair of the QIB Board of Trustees. “Each of them brings a unique set of expertise that will be invaluable assets for us as we look to establish the Quadram Institute as a world leader in food and health research.”
In addition to the move into the new Quadram Institute building in mid-2018, a new science strategy for the Quadram Institute will be launched, working at the interface of food science, gut biology, human health and disease.
Dr Celia Caulcott is Vice-Provost (Enterprise and London) UCL (University College London) where she leads on UCL’s enterprise strategy and embedding innovation and enterprise culture throughout the university. Celia has extensive experience working in and with the biopharmaceuticals industry, and prior to joining UCL, Celia was the Executive Director, Innovation and Skills at the BBSRC.
Dr Bénédicte Flambard is Global Head of the Business Unit of Live Therapeutics & Nutraceuticals at Boehringer Ingelheim leading the creation of a new business area at the interface of therapeutic nutrition and health. Her academic focus has been intestinal microbes and health, and host-microbe cross-talk, and previously she held several Vice President positions with Chr. Hansen, , the world Leader in microbial solutions.
Professor Peter J. Morgan is the Director of the Rowett Institute at the University of Aberdeen, overseeing the merger of the institute in 2008 and the development of a new £40 million building for the institute, including a state of the art human nutrition research facility, which opened in 2016. His research interests focus on the neurobiology of energy balance and biological rhythms, expanding recently into gut microbiome-brain interactions.
“I’m pleased to be able to welcome these high-calibre appointments to our Board of Trustees, and look forward to working with them to deliver the Quadram Institute’s mission,” said Professor Ian Charles, Director of the Quadram Institute. “The skills and experience that they, along with our other Trustees bring, give us a strong strategic oversight to launch the new institute, carry out excellent research, and translate our findings to really bring social and economic benefits to society.”
Dr Celia Caulcott
Dr Celia Caulcott is Vice-Provost (Enterprise and London) UCL (University College London) and is responsible for developing and leading the UCL strategies for both Enterprise and London. The former focuses on helping the outstanding staff and students of the university to make a difference to society and the world, in particular through embedding a culture of innovation and enterprise across the university. The UCL 2034 London strategy recognises the many facets of UCL as London’s global university, in particular recognising the multiple ways in which the university as a whole engages with the culture in London, the leadership of London and the opportunities for London.
Previously, Celia was the Executive Director, Innovation and Skills at the BBSRC, where she was responsible for developing and delivering BBSRC strategy for innovation. She worked in and with the biopharmaceuticals industry (including Celltech Ltd, ICI Pharmaceuticals, the Wellcome Foundation and various UK early stage biotechs) and the Wellcome Trust on the Human Genome Project.
Celia has an honours degree in Microbiology from Newcastle University and a PhD in pharmaceutical microbiology from Aston University.
Dr Bénédicte Flambard
Bénédicte currently is Global Head of the Business Unit of Live Therapeutics & Nutraceuticals at Boehringer Ingelheim, the #2 Global Leader specialized in Pharmaceuticals and Vaccines for Production and Companion Animals. She leads the creation of a new business area at the interface of Therapeutic Nutrition and Health, combining novel microbial based bio-therapeutic and diagnostic approaches.
Previously, Bénédicte worked for Chr. Hansen, the world Leader in Microbial Solutions, holding several Vice President positions, serving the Health Supplements for Pharma, OTC, Infant Formula as well as Agricultural Industries (Animal Feed & Plant). In parallel to core business, she was seeding and developing Growth Opportunities into Start Up businesses- one focusing exclusively on Microbiome- from Discovery of new micro-organisms to Scale up and Pilot Manufacture for Pharma Industries. She holds diverse Scientific Advisory roles for research Institutions, such as Panel of INRA’s Microbiology and Food Chain Division, and provides consulting services to organizations in the sectors of consumer goods, pharmaceuticals and technology.
Bénédicte holds a Master of Administration, with specialties in business models in emerging economies from the University of Bath (2011, UK); a PhD in Molecular Genetics and Microbial Physiology from INRA (National Institute of Agronomic, Jouy en Josas) and the University of Lyon in 1999; and a Master in Corporate Entrepreneurial Leadership from the Centre for Technology Economics & Management (2008, Denmark). Her scientific academic focus had been within the engineering of intestinal microbes to deliver enhanced health properties within the Cardiovascular and Immune domains, and more recently on host-microbe cross-talks.
Professor Peter J. Morgan
Peter Morgan is the Director of the Rowett Institute (RI) at the University of Aberdeen. As Director and CEO of the Rowett Research Institute (RRI), he led the merger of RRI with the University of Aberdeen to create RI in 2008. A key part of this was the development of a new £40 million Rowett Institute incorporating a state of the art human nutrition research facility on the University’s Medical School Campus, which he spearheaded and which was opened in April 2016.
As Director, he is responsible for the strategic direction of the Rowett Institute, part of which involves delivery of a strategic grant funded by Scottish Government worth ca £8 million per annum. This involved overseeing research across a wide spectrum of nutrition, including obesity, metabolic and gut health and life-course nutrition
Between 2008 and 2014 he served as a Vice-Principal at the University of Aberdeen, where he was involved in the strategic management of the University, particularly in relation to research and the Research Excellence Framework.
His personal research interests are in the neurobiology of energy balance as well biological rhythms. (http://www.abdn.ac.uk/rowett/research/peter-morgan.php). More recently this has been expanded to include gut microbiome-brain interactions. His research has been funded through grants from BBSRC, MRC and though strategic alliances with industry (pharma) and from Scottish Government and this has produced recognized impact. http://www.abdn.ac.uk/clsm/research/impact/valdoxan-antidepressant
He is, or has been, a member of numerous scientific committees and working groups focus on research and policy related to nutrition, diet and health in Scotland and across the UK and Europe, including with BBSRC and MRC.
He was elected a Fellow of the Royal Society of Edinburgh in 2002.